{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:56:12Z","timestamp":1788850572367,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.intimp.2022.108727","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T20:25:00Z","timestamp":1649276700000},"page":"108727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Toxicity profile of treatment with PD-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study"],"prefix":"10.1016","volume":"108","author":[{"given":"Hugo S.","family":"Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassia R.P.","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudimar P.","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.A.","family":"Wainstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Drummond-Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.intimp.2022.108727_b0005","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"1","author":"Gonzales","year":"2018","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in cancer immunotherapy","volume":"52","author":"Hedge","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri3442","article-title":"The integration of T cell migration, differentiation and function","volume":"13","author":"Masopust","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"7637","key":"10.1016\/j.intimp.2022.108727_b0025","first-page":"321","article-title":"Elements of cancer immunotherapy and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Review"},{"issue":"3","key":"10.1016\/j.intimp.2022.108727_b0030","first-page":"325","article-title":"Prote\u00ednas de checkpoint imunol\u00f3gico como novo alvo da imunoterapia contra o c\u00e2ncer: revis\u00e3o da literatura","volume":"45","author":"Teixeira","year":"2019","journal-title":"HU Ver."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4046\/trd.2017.0120","article-title":"Tumor immunology and immune checkpoint inhibitors in non-small cell lung cancer","volume":"81","author":"Jung","year":"2018","journal-title":"Tuberc. Respir. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.108727_b0040","first-page":"1","article-title":"Recent advances in targeting CD28 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory Pathways in Immunotherapy for Cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108727_b0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2022.108727_b0055","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.intimp.2022.108727_b0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt-2016-0029","article-title":"Immune checkpoint inhibitors side effects and management","volume":"8","author":"Kourie","year":"2016","journal-title":"Immunotherapy"},{"issue":"18","key":"10.1016\/j.intimp.2022.108727_b0065","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Vassiliki","year":"2016","journal-title":"N. Eng. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0070","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Ann. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108727_b0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2217\/imt.15.49","article-title":"Programmed death-1 & its ligands: promising targets for cancer","volume":"7","author":"Shrimali","year":"2015","journal-title":"Immunotherapy"},{"issue":"15","key":"10.1016\/j.intimp.2022.108727_b0080","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"Pd-L1 regulates the development, maintenance, and function of induced regulatory t cells","volume":"206","author":"Francis","year":"2009","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.108727_b0085","first-page":"148","article-title":"Imunoterapia- uma revis\u00e3o sobre os novos horizontes no combate ao c\u00e2ncer","volume":"99","author":"Junior","year":"2020","journal-title":"Rev Med S\u00e3o Paulo"},{"key":"10.1016\/j.intimp.2022.108727_b0090","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa). Consulta subst\u00e2ncia, 2021. https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/25351308360201510\/?substancia=25853 (accessed 01 October 2021)."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/cancers14010122","article-title":"Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives","volume":"14","author":"De Mello","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.intimp.2022.108727_b0100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s10038-018-0450-y","article-title":"Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention","volume":"63","author":"Fathi","year":"2018","journal-title":"J. Hum. Genet."},{"issue":"13","key":"10.1016\/j.intimp.2022.108727_b0105","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-Related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2022.108727_b0110","first-page":"1","article-title":"The future of cancer diagnosis, treatment and surveillance: A systemic review on immunotherapy and Immuno-PET Radiotracers","volume":"26","author":"Libernini","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2022.108727_b0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints PD-1, PD-L1, CTLA-4: new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.intimp.2022.108727_b0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2022.108727_b0130","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.intimp.2022.108727_b0135","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.intimp.2022.108727_b0140","first-page":"1","article-title":"Toxicities of Immunotherapy for the Practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108727_b0145","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"issue":"17","key":"10.1016\/j.intimp.2022.108727_b0150","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108727_b0155","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jgo.2018.07.015","article-title":"The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population","volume":"10","author":"Sattar","year":"2019","journal-title":"J. Geriatric Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108727_b0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. Med."},{"issue":"11","key":"10.1016\/j.intimp.2022.108727_b0170","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0094","article-title":"Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.intimp.2022.108727_b0175","first-page":"1","article-title":"Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small-cell lung cancer (NSCLC) in the real-world","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2022.108727_b0180","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3389\/fonc.2021.667650","article-title":"Assessment of the Clinical Trials Safety Profile of PD-1\/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis","volume":"11","author":"Tian","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108727_b0185","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol."},{"issue":"35","key":"10.1016\/j.intimp.2022.108727_b0190","doi-asserted-by":"crossref","first-page":"59901","DOI":"10.18632\/oncotarget.18316","article-title":"Effectiveness and safety of PD-1\/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget."},{"issue":"11","key":"10.1016\/j.intimp.2022.108727_b0195","first-page":"2016","article-title":"Educational interventions for the management of cancer-related fatigue in adults","volume":"24","author":"Bennet","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0200","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.intimp.2022.108727_b0205","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.2217\/fon-2018-0868","article-title":"Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis","volume":"15","author":"Tartarone","year":"2019","journal-title":"Future Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108727_b0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/imt-2020-0224","article-title":"Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis","volume":"13","author":"Petrelli","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0215","first-page":"16","article-title":"Comparative efficacy and safety of immunotherapies targeting the PD-1\/PDL1 pathway for previously treated advanced non-small-cell lung cancer: ABayesian network meta-analysis","volume":"142","author":"Abdulaali","year":"2019","journal-title":"Crit. Rev. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108727_b0225","first-page":"1","article-title":"Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens","volume":"87","author":"Jiannan","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0230","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.intimp.2022.108727_b0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2022.108727_b0240","first-page":"1","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: A meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"43","key":"10.1016\/j.intimp.2022.108727_b0245","first-page":"11","article-title":"Diretrizes brasileiras de manejo de toxicidades imunomediadas associadas ao uso de bloqueadores de correceptores imunes","volume":"13","author":"Wainstein","year":"2017","journal-title":"Braz. J. Oncol."},{"issue":"20","key":"10.1016\/j.intimp.2022.108727_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000015731","article-title":"Risk of dermatologic and mucosal adverse events associated with PD-1\/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2022.108727_b0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treatm. Rev."},{"issue":"21","key":"10.1016\/j.intimp.2022.108727_b0260","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.108727_b0265","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:50:38Z","timestamp":1761587438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":53,"alternative-id":["S1567576922002119"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108727","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity profile of treatment with PD-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108727"}}